Kazia Therapeutics (KZIA) Other Accumulated Expenses (2022)
Kazia Therapeutics (KZIA) posted Other Accumulated Expenses of $515471.1 for Q4 2022, up 360.87% on a QoQ basis from $111847.4 in Q2 2022.
Kazia Therapeutics (KZIA) has 1 years of Other Accumulated Expenses data on file, last reported at $515471.1 in Q4 2022.
- In Q4 2022, Other Accumulated Expenses changed N/A year-over-year to $515471.1; the TTM figure through Dec 2022 stood at $515471.1 (changed N/A YoY), while the FY2022 annual figure was $111847.4, changed N/A from the prior year.
- Other Accumulated Expenses improved to $515471.1 in Q4 2022, from $111847.4 in the prior quarter.
- Across five years, Other Accumulated Expenses topped out at $515471.1 in Q4 2022 and bottomed at $111847.4 in Q2 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Kazia Therapeutics | 1.55 Bn | 1.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 515,471.05 |
| Jun 30, 2022 | 111,847.45 |